Image

The innovative biopharmaceutical company PROMOMED informs about the intra-group transaction aimed at accelerating the development and market launch of new innovative medicines

02.08.2024

Corporate
For investors
Industry development

August 02, 2024, Moscow. The leading innovative biopharmaceutical company PJSC PROMOMED (formerly and hereinafter referred to as PROMOMED, the Company, the Issuer and, together with its subsidiaries, the Group) informs about an interested–party intra–group transaction.

PROMOMED contributes 1.1 billion rubles to the property of its controlled company PROMOMED RUS LLC. The perimeter of responsibility of PROMOMED RUS LLC includes: the development of new technologies and products, medical research, registration of medicines, the patent department and the product transfer group into production. This amount represents a portion of the funds raised as part of the initial public offering of PROMOMED shares (IPO), which ended in July 2024.

All contribution funds will remain within the PROMOMED Group and, as planned in the framework of the IPO, will be used to accelerate research and development of medicines, medical research, patenting, registration and market launch of new innovative drugs.

PJSC PROMOMED is consolidating PROMOMED RUS LLC (the company's R&D center), PROMOMED DM LLC (sales and issuer of bonds) and Biochemist JSC, a production site in Saransk.

Alexander Yefremov, CEO of PJSC PROMOMED, commented:

"We consistently and transparently implement our Company's development strategy and primarily invest in research and development of new high-tech drugs for the treatment of socially significant diseases such as oncology, obesity, HIV infection, neurodegenerative diseases, etc. Investments in pharmaceutical innovations are an essential contribution to the sustainable development and drug safety of our country."

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office